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Type I Interferon Potentiates IgA 
Immunity to Respiratory Syncytial 
Virus Infection During Infancy
Diego R. Hijano  1, David T. Siefker2, Bishwas Shrestha3, Sridhar Jaligama3, Luan D. Vu2, 
Heather Tillman  4, David Finkelstein5, Jordy Saravia3, Dahui You3 & Stephania A. Cormier2
Respiratory syncytial virus (RSV) infection is the most frequent cause of hospitalization in infants 
and young children worldwide. Although mucosal RSV vaccines can reduce RSV disease burden, 
little is known about mucosal immune response capabilities in children. Neonatal or adult mice were 
infected with RSV; a subset of neonatal mice received interferon alpha (IFN-α) (intranasal) prior to RSV 
infection. B cells, B cell activating factor (BAFF) and IgA were measured by flow cytometry. RSV specific 
IgA was measured in nasal washes. Nasal associated lymphoid tissue (NALT) and lungs were stained 
for BAFF and IgA. Herein, we show in a mouse model of RSV infection that IFN-α plays a dual role as 
an antiviral and immune modulator and age-related differences in IgA production upon RSV infection 
can be overcome by IFN-α administration. IFN-α administration before RSV infection in neonatal 
mice increased RSV-specific IgA production in the nasal mucosa and induced expression of the B-cell 
activating factor BAFF in NALT. These findings are important, as mucosal antibodies at the infection 
site, and not serum antibodies, have been shown to protect human adults from experimental RSV 
infection.
Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infections in infants and 
young children worldwide and is associated with high rates of hospitalization1. Globally, RSV infections occur 
in approximately 64 million people and lead to 160,000 infant deaths each year2. In the United States, RSV infec-
tions are annually associated with 85,000–144,000 infant hospitalizations2. Infants younger than 3 months are at 
highest risk for RSV-related hospitalizations, most of which occur during the first year of life3,4. Age is an impor-
tant risk factor for severe RSV in children5,6. Increased severity of RSV infections in young infants can be due to 
structural immaturity of airways7 and/or immaturity of the immune system8–10.
There are well-defined differences between innate and adaptive immune responses of infants and adults11,12. 
Neonatal mouse models of RSV infection have revealed the key role of age-dependent differences in RSV patho-
genesis13–16, of which those related to type I interferon (IFN) production are of special interest. RSV is a poor 
inducer of IFN17–19, and nonstructural proteins NS1 and NS2 can suppress IFN production20,21. Neonatal mice 
cannot induce a robust type I IFN immune response, which is consistent with findings from human studies22,23. 
However, RSV infection–induced IFN-alpha (IFN-α) production is significantly higher in adult mice than in 
neonatal mice22,23, suggesting that RSV can suppress type I IFN production but responses of neonatal and adult 
mice are distinct. Furthermore, engagement of type I IFN pathways is associated with T helper type 1 (Th1)–
biased immune responses and less airway hyper-reactivity after RSV reinfection in mice24. Age-based differences 
in type I IFN production and pathways involving B-cell proliferation and maturation have been reported in very 
young humans25.
The mucosal immune system is an integrated network of tissues, cells, and effector molecules that protects 
the host from infections and environmental insults at mucosal surfaces26. Mucosal surfaces are immunologi-
cally unique, acting both as a barrier and as the primary interface between the host and physical environment 
from which the pathogen arrives26,27. Mucosal antibodies against RSV, especially IgA, mediate protection against 
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experimental RSV infection in adults28,29. Vissers et al. proposed that mucosal IgG levels have higher correlation 
with disease protection than do serum IgG levels30. Despite the heightened interest in developing mucosal vac-
cines against various types of microbial pathogens for very young children31–33, little is known about the mucosal 
immune response capabilities of this patient population.
In this study, we use adult and neonatal mice infected with RSV to reveal the critical role of IgA at the nasal 
mucosa and an age-dependent deficit in IgA production. We show that this deficit in neonatal mice is due to 
decreased B-cell activation and can be ameliorated by IFN-α supplementation to the nasal mucosa before RSV 
infection.
Results
IFN-α decreases viral load and attenuates the immune response. Our previous work demon-
strated that adult mice have higher type I IFN responses relative to neonates after being infected with RSV. 
Further, administration of IFN-α induced protection against RSV infection in neonates (i.e. decreased Th2-
biased immunopathogenesis and attenuated airways hyperreactivity, pulmonary inflammation, and mucus 
hyperproduction)23. To further explore the protective effect of IFN-α in the immune response to RSV, host gene 
expression analysis on NALT and lung homogenates was performed at 4 days post-infection (dpi), when RSV 
viral load peaks in the respiratory tract15. Principal component analysis (PCA) showed significant differences in 
gene expression across the groups in both NALT and lungs (Fig. 1a and Supplementary Fig. 2e). PCA shows that 
first component defines a gradient of expression that distinguishes NR, INR, and B-cell depleted mice (Fig. 1a). 
RSV viral load in NALT was significantly lower in neonatal mice receiving IFN-α prior to RSV infection than 
in neonatal mice not receiving IFN-α or adult mice infected with RSV (Fig. 1b). Interestingly, RSV viral load in 
Figure 1. IFN-α decreases viral load and modulates gene expression upon RSV infection. (a) Principal 
component analysis of nasal-associated lymphoid tissue (NALT) from RSV-infected neonatal mice receiving 
IFN-α (INR/red), placebo (NR/blue), or anti CD-20 (green) 16 h before infection. (b) NS1 gene expression in 
NALT from RSV-infected adult (gray) and neonatal mice receiving IFN-α (IRN/red), placebo (NR/blue), or 
anti CD-20 (green) 16 h before infection. (c) IFN-α 4 gene expression in NALT from RSV-infected neonatal 
mice receiving IFN-α (INR/red) or placebo (NR/blue) 16 h before infection. (d) IFN-α gene expression from 
RSV-infected neonatal mice receiving IFN-α (INR), placebo (NR), or anti CD-20 16 h before infection. (e) 
Heatmap analysis of data corresponding to fold change in the expression of indicated markers in NALT from 
RSV-infected neonatal mice receiving IFN-α (INR/red) or placebo (NR/blue) 16 h before infection. n = 3–5; 
N = 2 *P < 0.05, **P < 0.01.
www.nature.com/scientificreports/
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the lungs exhibited a similar pattern (i.e. significantly lower virus in neonatal mice receiving IFN-α prior to RSV 
infection than in neonatal mice not receiving IFN-α Supplementary Fig. 2f). A third group of neonatal mice 
depleted of B cells had significantly higher viral load compared to all other groups. Interestingly, IFN-α admin-
istration induced the expression of its homolog gene in NALT, suggesting host modulation of gene expression 
(Fig. 1c). Furthermore, IFN-α suppressed the immune response, as evidenced by decreased expression of genes 
involved in granulocyte migration and neutrophil-mediated immunity and upregulation of genes controlling the 
inflammatory response, such as those involved in the negative regulation of T-cell proliferation and MAPK activ-
ity (Fig. 1e and Supplementary Fig. 2c). To determine whether these results are due to IFN administration prior 
to infection, a result of an attenuated infection or a combination of both, we repeated the experiment comparing 
mice that received IFN-α with a group on neonatal mice that received palivizumab prior to RSV infection. There 
were over 7000 genes that are statistically significantly different between the groups (Supplementary Fig. 2d). 
Although some of the genes involved in T cell regulation and inactivation of MAP K were also expressed and 
some overexpressed in the group treated with palivizumab (Supplementary Table 1), many of the genes involved 
in granulocyte migration and neutrophil mediated immunity were further overexpressed in those treated with 
palivizumab (Supplementary Table 2). Consistent with previous data published by our group, upon reinfection, 
neonatal mice receiving IFN-α had significantly lower inflammation in their lower respiratory tract than did 
age-matched control mice, suggesting that effects of IFN-α on the immune response against RSV go beyond 
primary infection (Supplemenatry Fig. 3). Following administration of IFN-α in neonatal mice, we observed 
decreases in RSV viral load and increases in IFN-α gene expression (Fig. 1b,c). We analyzed gene expression data 
from mice pretreated with IFN-α and mice pretreated with palivizumab (Supplementary Table 3). Both interven-
tions are known to reduce viral load and attenuate infection. Mice pre-treated with palivizumab exhibited strong 
overexpression of several IFN-α genes when compared to those who received IFN-α prior to RSV infection 
(Supplementary Table 3). Taken together, these findings suggest that upon RSV infection, IFN-α plays a dual role 
as an antiviral and immune modulator.
IFN-α increases B cells and B-cell activation. To determine the role of B cells upon RSV infection, flow 
cytometry was performed on NALT to determine the percentage of CD19+B220+ lymphocytes. There was no 
difference in the percentage of CD19+B220+ lymphocytes among groups at 7 or 21 dpi (Fig. 2a,c). However, at 
14 dpi, neonatal mice receiving IFN-α or adult mice had a significantly higher percentage of CD19+B220+ lym-
phocytes than did neonatal mice infected with RSV or control (Fig. 2b). There were no differences at 7 dpi after 
reinfection in NALT or lungs (Fig. 2d,e). Activated B cells, as measured by the percentage of B220+CD19+CD69+ 
lymphocytes, were higher in lungs of reinfected adult mice than of reinfected neonatal mice. Interestingly, the 
highest increase in activated B cells occurred in lungs of neonatal mice receiving IFN-α, suggesting a role for 
IFN-α in B-cell activation upon reinfection with RSV (Fig. 2f,g).
NALT was identified in H&E–stained sections within the lamina propria at the level of nasopharyngeal ducts, 
with variable formation also observed around the nasopharynx across different time points after RSV infection. 
Developing NALT in younger mice and fully formed NALT in adult mice had both PAX5-positive and -negative 
cells. PAX5-positive cells formed distinct aggregates that often represented organizing germinal centers, which is 
consistent with the role for PAX5 in B-cell lymphopoiesis34. PAX5-positive cells were also present in low numbers 
at all levels of the nasal cavity (Fig. 2h). There were no apparent differences in PAX5-positive cells in NALT after 
primary infection. Adult mice had an overall increase in the cellularity of lungs, which was characterized by scat-
tered clusters of peribronchiolar inflammation and organized bronchus-associated lymphoid tissue. Compared 
with neonatal mice, these histologic changes were present at 7, 14, and 21 dpi. Upon reinfection, PAX5 cells in 
neonatal mice receiving IFN-α and in adult mice were comparable. Taken together, these findings suggest that 
both age and level of IFN-α play a key role in B-cell production, induction of mucosal-associated lymphoid tissue, 
and immune cell activation in the respiratory tract of mice after primary RSV infection or re-infection.
IFN-α increases BAFF and APRIL expression. B-cell activating factor/tumor necrosis factor ligand 
superfamily member 13B (BAFF/Tnfsf13b) and a proliferation-inducing ligand/tumor necrosis factor ligand 
superfamily member 13 (APRIL/Tnfsf13), along with receptors tumor necrosis factor receptor superfamily mem-
ber 13 C (BAFF-R/Tnfrsf13c), transmembrane activator and CAML interactor/tumor necrosis factor receptor 
superfamily member 13B (TACI/Tnfrsf13b), and B-cell maturation antigen/tumor necrosis factor receptor super-
family member 17 (BCMA/Tnfrsf17) have been implicated in T-cell–independent IgA production35,36. To deter-
mine the role of IFN-α in B-cell activation, expression levels of these key mediators were determined in NALT. 
After RSV infection, expression of BAFF and APRIL was higher in adult mice than in neonatal mice. Neonatal 
mice receiving IFN-α before RSV infection had higher expression of BAFF and APRIL than did neonatal mice 
not receiving IFN-α (Fig. 3a,b). There was no difference in the expression of BAFF-R between neonatal mice 
receiving or not receiving IFN-α before RSV infection (Fig. 3c). Class switching and differentiation of B cells to 
plasmablasts upon exposure to IFN-α/β from plasmocytoid dendritic cells (pDCs) is associated with downreg-
ulation of TACI37. Adult mice had lower expression of TACI than did neonatal mice and this expression seemed 
lower after IFN-α administration, although these differences were not significant (Fig. 3d). Interestingly, BCMA 
expression, which plays a role in maintaining the survival of long-lived plasma cells38, was significantly higher in 
neonatal mice receiving IFN-α and in adult mice when compared to controls and neonatal mice infected with 
RSV that did not receive IFN-α (Fig. 3e). When comparing mice pretreated with palivizumab with those treated 
with IFN-α, the former had a significant increase in BAFF expression (logFC of INR vs Palivizumab −2.276; 
FDR 0.006. Supplementary Table 3), further confirming that inducing IFN-α gene expression leads to increase 
expression of BAFF. Flow cytometry analysis for the presence of BAFF-R+ cells revealed that adult and neonatal 
mice treated with IFN-α had significantly higher numbers of CD19+B220+BAFF-R+ cells in NALT at 7 and 21 
dpi (Fig. 4a,b,d), but there was no difference at 14 dpi (Fig. 4c). After reinfection, the response pattern in NALT 
www.nature.com/scientificreports/
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Figure 2. IFN-α administration before RSV infection correlates with increased B-cell lymphopoiesis in the 
respiratory tract after RSV infection in vivo. (a–d) Percentage of B220+CD19+ lymphocytes in NALT from RSV-
infected adult (AR) and neonatal mice receiving IFN-α (INR) or placebo (NR) 16 h before RSV infection. Controls 
were inoculated with media. (a) 7 dpi; (b) 14 dpi; and (c) 21 dpi; (d,e) B cells in NALT and lungs upon secondary 
infection with RSV. (d) Percentage of B220+CD19+ lymphocytes in NALT from RSV-infected adult (ARR) and 
neonatal mice receiving IFN-α (INRR) or placebo (NRR) 16 h before RSV infection 7 days post-secondary infection. 
Controls were inoculated with media. (e) Percentage of B220+CD19+ lymphocytes in lungs from RSV-infected 
adult (ARR) and neonatal mice receiving IFN-α (INRR) or placebo (NRR) 16 h before RSV infection and 7 days 
post-secondary infection. Controls were inoculated with media. (f–g) B-cell activation in NALT and lungs from RSV-
infected adult (ARR) and neonatal mice receiving IFN-α (INRR) or placebo (NRR) 16 h before RSV infection and 
reinfected 4 weeks after primary infection. (f) Representative flow cytometry panels of B220+CD19+CD69+ cells; (g) 
Percentage of B220+CD19+CD69+ lymphocytes in NALT and lungs. (h) IHC analysis demonstrating expression of 
PAX5 protein in NALT and lungs of RSV-challenged groups and control mice at 7, 14, and, 21 days post infection, as 
well as, after reinfection. Magnification 200×; scale bar = 100 μm. n = 3–5; N = 2 *P < 0.05, **P < 0.01.
www.nature.com/scientificreports/
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and lungs was different. Neonatal mice receiving IFN-α and adult mice had a significantly higher percentage of 
CD19+B220+BAFF-R+cells in NALT, but only adult mice had an increased number of these cells in the lower 
respiratory tract (Fig. 4e,f). BAFF- positive cells were often concentrated in germinal centers, but were also found 
in other areas of NALT, with low numbers of positive cells being present at all levels of the nasal cavity in all 
groups. NALT of adult mice contained more BAFF-positive cells than that of neonatal mice, appearing as early 
as 7 dpi (Fig. 4g). BAFF-positive cells corresponded to areas of PAX5 positivity and germinal center formation 
in NALT in all groups, and they were predominant in adult mice at 7 dpi (Fig. 4g). Also, BAFF was expressed in 
both the mucosal epithelium and submucosal glands. Lungs of neonatal mice receiving IFN-α and of adult mice 
had comparable numbers of BAFF-positive cells at 21 dpi, and these numbers were higher than in neonatal mice 
not receiving IFN-α (Fig. 4g). Taken together, these data suggest a role for IFN-α in B-cell activation through 
BAFF/Tnfsf13b and APRIL/Tnfsf13 in response to RSV infection.
Age and IFN-α determine IgA production. To determine the role of age and IFN-α in IgA production 
upon RSV infection, NALT of mice was harvested at different time points after primary infection. B cells express-
ing surface IgA were measured by flow cytometry. Mice that received IFN-α had significantly higher proportions 
of IgA-expressing B cells at 7 dpi (Fig. 5a,b). At 14 dpi all infected mice had higher numbers of IgA-expressing 
B cells than did uninfected mice (Fig. 5c). At 21 dpi, neonatal mice receiving IFN-α and adult mice had signif-
icantly higher numbers of IgA-expressing B cells than did neonatal mice and controls (Fig. 5d). Interestingly, 
upon reinfection, this difference was notable in NALT as early as 7 dpi (Fig. 5e). IgA-expressing B cells in lungs 
were significantly increased in adult mice and slightly elevated in mice receiving IFN-α, but the latter increase 
was not significant (Fig. 5f). Similar results were observed upon reinfection when intracellular IgA was measured 
(Supplementary Fig. 4a–c). IgA-positive cells were present within and around NALT and at all histologic levels of 
the nasal cavity. The maximum increase in IgA-positive cells occurred in adult mice at 7, 14, and 21 dpi and to a 
lesser extent in neonatal mice receiving IFN-α at 21 dpi compared with controls and neonatal mice not receiving 
IFN-α (Fig. 5g). IgA-positive cells correlated with fully developed NALT, IFN-α administration before RSV infec-
tion, increased age of mice at the time of viral challenge, and secondary infection to RSV.
IgA-positive cells were observed in lungs of adult mice adjacent to areas of inflammation and correlated with 
IgA+ secretions. Interestingly, IFN-α administration did not increase IgA in lungs upon primary infection, but 
correlated with an increase in IgA-positive cells in lungs upon reinfection (Fig. 5g).
Lastly, RSV-specific IgA levels were measured in nasal wash, NALT, BAL, and lung homogenates (Fig. 6 and 
Supplementary Fig. 5a–c). As expected, RSV-specific IgA in nasal washes was comparable between neonatal mice 
receiving IFN-α and adult mice at 14 dpi (Fig. 6). Taken together, these findings suggest that the effect of age in 
IgA production upon RSV infection can be overcome by IFN-α administration.
Figure 3. BAFF and APRIL expression is enhanced by IFN-α in NALT upon primary infection with RSV. Gene 
expression in NALT 7 days post infection with RSV from RSV-infected adult (AR) and neonatal mice receiving 
IFN-α (INR) or placebo (NR) 16 h before RSV infection. Controls were inoculated with media. (a) Tnfsf13b 
(BAFF); (b) Tnfsf13 (APRIL); (c) Tnfrsf13c (BAFF-R); (d) Tnfrsf13b (TACI) and (e) Tnfrsf17 (BCMA). n = 3–5; 
N = 2 *P < 0.05, **P < 0.01.
www.nature.com/scientificreports/
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Figure 4. BAFF-R–positive cells are increased in NALT by IFN-α administration or age in NALT upon primary 
infection with RSV. BAFF-R–positive cells by flow cytometry in NALT and lungs from RSV-infected adult (AR) 
and neonatal mice receiving IFN-α (INR) or placebo (NR) 16 h before RSV infection and adult (ARR) and 
neonatal mice receiving IFN-α (INRR) or placebo (NRR) 16 h before RSV infection and reinfected 4 weeks after 
primary infection. (a) Representative flow cytometry panels of B220+CD19+BAFF-R+ cells. (b–f) Percentage of 
B220+CD19+BAFF-R+ cells at different time points. (b) 7 dpi; (c) 14 dpi; (d) 21 dpi; (e) 7 days post-secondary 
infection in NALT; (f) 7 days post-secondary infection in lungs. (g) IHC analysis demonstrating expression 
of BAFF-R protein in NALT and lungs of RSV-challenged groups and control mice at 7, 14, and, 21 days post 
infection, as well as, after reinfection. Magnification 200×; scale bar = 100 μm. n = 3–5; N = 2 *P < 0.05, 
**P < 0.01.
www.nature.com/scientificreports/
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Figure 5. IgA-positive cells are increased in NALT by IFN-α administration or age upon primary infection 
with RSV. Surface IgA-positive cells by flow cytometry in NALT and lungs from RSV-infected adult (AR) 
and neonatal mice receiving IFN-α (INR) or placebo (NR) 16 h before RSV infection and adult (ARR) and 
neonatal mice receiving IFN-α (INRR) or placebo (NRR) 16 h before RSV infection and reinfected 4 weeks 
after primary infection. (a) Representative flow cytometry panels of B220+CD19+IgA+ cells; (b–f) Percentage 
of B220+CD19+IgA+ cells at different time points. (b) 7 dpi; (c) 14 dpi; (d) 21 dpi; (e) 7 days post-secondary 
infection in NALT; and (f) 7 days post-secondary infection in lungs. (g) IHC analysis demonstrating expression 
of IgA protein in NALT and lungs of RSV-challenged groups and control mice at 7, 14, and, 21 days post 
infection, as well as after reinfection. n = 3–5; N = 2 Magnification 200×; scale bar = 100 μm.
www.nature.com/scientificreports/
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Discussion
Our study highlights age-related differences in mucosal immune response against RSV infection in mice. IFN-α 
administration before RSV infection in neonatal mice induced BAFF and APRIL expression at levels compara-
ble with those in adult mice. Furthermore, IFN-α augmented the production of total IgA producing B cells and 
RSV-specific IgA levels in NALT and reduced inflammation upon reinfection.
We describe a dual role for IFN-α as an antiviral and immune modulator that goes beyond primary RSV 
infection. Early reduction of viral burden in the respiratory tract can have short and long term immune effects39. 
A previous study showed that when type I IFN pathways are reconditioned in neonatal mice upon RSV infection, 
DC numbers in the lungs increase and mice are protected from exacerbated airway disease upon RSV reinfection 
in adulthood24. Also, this is accompanied by a shift toward a Th1 response. Adult mice produce significantly 
higher levels of type I IFN in response to RSV infection than do neonatal mice23. Furthermore, IFN-α administra-
tion or passive transfer of adult pDCs (which can produce type I IFN) before RSV infection protects mice against 
airway hyper-reactivity and decreased pulmonary Th2 bias23. These results agree with our current findings that 
neonatal mice receiving IFN-α had the lowest viral load in nasal washes and less inflammation upon reinfection. 
Furthermore, gene expression analysis of mice treated with Palivizumab, which decreases infectivity and viral 
load in mice40,41, suggests that while some of the effects shown in Fig. 1 are indeed due to an attenuated infection, 
there is a distinct role for IFN-α administration on the mucosal immune response against RSV infection. Tripp 
et al. have recently reported that treatment with TRL3D3 (a monoclonal antibody targeting G) lead to enhanced 
IFN whereas anti-F protein Mab depressed the IFN response42. These mice had decreased airway inflammation, 
and improved lung function upon secondary infection, whereas mice treatead with anti-F had less IFN than 
mock infected animals42. Capella et al. showed that elevated titer to G was as well correlated with mild diseaseas 
as was titer to pre-F in infants with RSV infections suggesting that targeting G has an important role in clinical 
outcome43. These results confirm the role of IFN-α as an antiviral and an immune modulator upon RSV infection 
and supports our hypothesis that IFN is critical in the development of the mucosal immune response against RSV 
and that those effects can not be fully explained by attenuation of the infection.
We did not observe any differences in gene expression associated with B cell or BCR signaling when compar-
ing neonates with and without previous IFN-α administration. Differences in expression are for the entire lung 
and not specific to cell populations; thus the actual expression changes in specific cells may misrepresent expres-
sion in B cells or cells producing BAFF and TACI such as pDCs. When comparing mice treated with IFN with 
those who were B cell depleted, there are different GO terms related to BCR signaling. Interestingly, mice depleted 
of B cells had significantly higher viral load in NALT and lungs. B cell depletion has been shown to impair CD4+ 
T cell activation and clonal expansion in response to protein antigens and pathogen challenge. Furthermore, 
CD20 immunotherapy (such as the one we have used in our experiments) revealed that optimal antigen-specific 
CD4+ T cell priming requires B cells, and hence the difficulty in controlling viral replication44.
There was a discrete but significant increase in B-cell numbers in NALT of neonatal mice receiving IFN-α at 
14 dpi compared with uninfected controls. This can be explained by increased expression of BAFF and APRIL 
earlier in infection in both neonatal mice receiving IFN-α and adult mice. Further, we showed that expression of 
BAFF and APRIL after RSV infection differed by age (lower in neonatal mice than mature mice), and this differ-
ence was overcome by IFN-α administration. Besides being essential for B-cell expansion and survival45, BAFF 
is implicated in regulating T cell–independent antibody production46. BAFF has been localized in the infected 
respiratory epithelium of lungs from infants with fatal bronchiolitis47, and human airway epithelial cells produce 
BAFF in response to RSV infection in vitro48. However, this may not be sufficient to induce an immune memory 
response. There are well-defined age-related differences in the BAFF/BAFF-R pathway. BAFF-R expression is low 
Figure 6. RSV-specific mucosal IgA in the upper respiratory tract is increased by IFN-α administration before 
RSV infection. RSV-specific mucosal IgA in nasal washes at different time points from RSV-infected adult (AR) 
and neonatal mice receiving IFN-α (INR) or placebo (NR) 16 h before RSV infection. Controls received vehicle 
control before RSV infection. A subset of neonatal mice received IFN-α followed by media (IControl). Dotted 
line represents lower limit of detection of the assay. n = 3–5; N = 2.
www.nature.com/scientificreports/
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in newborns, and this is associated with decreased B-cell survival49. When B cells from human preterm neonates 
and adults are stimulated with recombinant BAFF, B cells from preterm neonates have less proliferation and lower 
expression of BAFF-R than those from adults. In fact, BAFF or APRIL cannot induce immunoglobulin secretion 
from neonatal B cells in vitro49. These observations can be explained by the lack of type I IFN production at young 
ages.
High titers of circulating antibodies against RSV in the blood can protect against lower respiratory tract infec-
tions50,51. However, there is increasing interest in mucosal antibodies from nasal washes, as they are localized to 
the first point of contact with RSV28,29,52. Vissers et al. showed that mucosal IgG had a higher correlation with 
RSV viral load and inflammation than did systemic IgG30. In two experimental human models of RSV, prior 
RSV-specific nasal IgA correlated significantly more strongly with protection from infection than did serum 
neutralizing antibodies28,29. Interestingly, one of these studies showed that only IgG levels remained high in the 
convalescence period, indicating the presence of a potential mechanism that explains multiple infections by RSV 
despite its relative antigenic stability28. We are currently exploring this aspect in our mouse model.
In conclusion, we showed an age-related difference in IgA production against RSV infection. Neonatal mice 
did not produce IgA in both the upper and lower respiratory tracts in response to RSV. This age-related differ-
ence in the immune response could be explained by lack of type I IFN signaling in neonatal mice, which in turn 
reduces B-cell activation and IgA class switching. With approximately 60 RSV vaccine candidates currently under 
development, insights into the mucosal immune response against RSV infection and its age-related differences 
are critical to identify and guide the development of effective immunologic adjuvants for vaccines, understand 
mechanisms underlying RSV reinfection and severity, and emphasize the need to consider differential interac-
tions between virus and host immune response at different ages.
Methods
Mice. BALB/c mice (Jackson Laboratories) were maintained in specific-pathogen-free facilities at the 
University of Tennessee Health Science Center (UTHSC), Memphis, TN. Mice to be bred were time mated, and 
pups born on the same date were used for experiments. NR, neonatal mice infected with RSV; INR, neonatal mice 
receiving IFN-α 16 h before RSV infection; AR, adult mice infected with RSV; NRR, adult mice infected with RSV 
as neonates and reinfected 4 weeks later; INRR, adult mice infected with RSV receiving IFN-α 16 h before RSV 
infection as neonates and reinfected 4 weeks later; ARR, adult mice infected with RSV twice at a gap of 4 weeks 
(Supplementary Fig. 6). N = replicate experiments with n animals per group per experiment. All animal protocols 
were performed in accordance with the Guide for the Care and Use of Laboratory Animals and approved by the 
Institutional Animal Care and Use Committee at UTHSC.
IFN-α treatment. Mouse recombinant IFN-α A (12105-1) was purchased from PBL Interferon Source 
(Piscataway, NJ). Sixteen hours before RSV infection, 2 × 103 units (dose extrapolated from that used in adult-
mice)53 of IFN-α was intranasally instilled into pups in 10 μL of PBS containing 0.1% bovine serum albumin 
(BSA). Control pups (NS) received 10 μL of PBS containing 0.1% BSA.
B-cell depletion. Purified anti-mouse CD20 antibody was purchased from BioLegend. Sixteen hours before 
RSV infection, 250 µg of Ultra-LEAF™ purified mAb anti-mouse CD20 was intraperitoneally injected into pups. 
In addition, 10 µg was intranasally instilled.
Palivizumab treatment. After reconstitution from lyophilized powder in 100 μl of sterile water, a dose of 
50 mg/kg (1.25 mg per mouse) was administered once intraperitoneally, 24 h before intranasal inoculation, as 
described elsewhere40,41.
RSV infection. Human RSV strain A2 (Advanced Biotechnologies) was propagated in Vero cells (ATCC) 
grown in HyClone™ serum-free media (ThermoFisher Scientific), harvested using a standard protocol23, and 
stored at –80 °C until use. Mice (5-day-old pups or 6- to 8-week-old adults) were intranasally infected with RSV 
in serum-free media at a dose of 2 × 105 tissue culture infectious dose 50 per gram of body weight. Control mice 
received serum-free media.
NALT dissection. NALT tissues were collected as previously described54. Briefly, euthanized mice were 
decapitated. After the lower jaw, including tongue, was removed, palates were scored by cutting along the inside 
edges of the upper molars with a scalpel and then peeling the tissue away from the roof of the mouth. Once 
exposed the entire hard palate and NALT were excised.
Real-time PCR. RNA was isolated from frozen nasal-associated lymphoid tissue (NALT) and lungs by using 
the RNeasy Plus Mini Kit (Qiagen) as per the manufacturer’s instructions. Real time RT-PCR was performed 
using the SuperScript™ III Platinum™ One-Step qRT-PCR Kit (Life Technologies).
Simple relative quantification of target gene expression normalized to Hprt was performed using the 2−ΔΔCt 
method as described elsewhere55. Control group changed depending on the experiment. Control groups for 
Fig. 1b was NR (neonatal mice infected with RSV); for Fig. 3 was uninfected neonate; and for Supplementary 
Fig. 2f was NR.
The following primers were used: NS1, forward primer: 5′-CACAACAATGCCAGTGCTACAA-3′; NS1, reverse 
primer: 5′-TTAGACCATTAGGTTGAGAGCAATGT-3′; Hprt forward primer: 5′-GGCTCCGTTATGGCGA 
CCCG-3′; Hprt reverse primer: 5′-CGAGCAAGACGTTCAGTCCTGTCC-3′. TaqMan™ primers and probes for 
Tnfsf13b, Tnfrsf13c, Tnfrsf13b, Tnfsf13, Tnfrsf17, and Ifn-α4 were purchased from Applied Biosystems.
www.nature.com/scientificreports/
1 0SCIenTIfIC REPORTS |  (2018) 8:11034  | DOI:10.1038/s41598-018-29456-w
Flow cytometry. Single cells were isolated and labeled with a fixable viability dye and antibodies to IgA-FITC 
(BD Biosciences, #553478); IgA-PE (BD Biosciences, #562141); CD69-BV786 (BD Biosciences, #56468); 
B220-BV605 (BD Biosciences, #563708); CD19-PerCp-Cy5.5 (BD Biosciences, #551001); CD11c-PE-CY7 (BD 
Biosciences, #558079); CD317 (pDCA1)-BV421 (BD Biosciences, #566431); CD268 (BAFF Receptor)-APC (eBi-
oscience, #17-9117-42); and LIVE/DEAD™ Near IR- Dead Cell Stain Kit (Molecular Probes, #L34975). Isotype 
controls were used to set the photomultiplier tube (PMT) voltages. Single color controls were used for compensa-
tion. Stained cells were assayed on the LSRFortessa™ cell analyzer (BD Biosciences), and flow data were analyzed 
and plotted using BD FACSDiva™ (ver. 8). Singlet live cells were gated before further analysis (Supplementary 
Fig. 1).
RSV specific IgA ELISA. Nunc-Immuno MaxiSorp™ plates were coated with RSV (105 plaque-forming 
units/mL) overnight. Test samples were diluted and incubated in microtiter wells for 45 min alongside mouse IgA 
standards, using IgA ELISA (Life Diagnostics, #IGA-1). Horseradish peroxidase conjugate was added and incu-
bated for 45 min, followed by incubation with TMB reagent for 20 min at room temperature. Color development 
was stopped by adding the stop solution, and optical density was spectrophotometrically measured at 450 nm. The 
IgA concentration was derived from a standard curve with a range of 0.93–30 ng/mL.
Pathology analysis. Mice heads and lungs were harvested and fixed with 10% neutral buffered formalin 
for 72 h before standard histologic processing, which included decalcification of bony tissues, sectioning, and 
hematoxylin-and-eosin (H&E) staining. Immunohistochemistry (IHC)-based labeling was performed using a 
Discovery XT autostainer (Ventana Medical Systems) or a BOND RX autostainer (Leica Biosystems). Primary 
antibodies used to label serial sections of lungs and NALT were anti-BAFF antibody (BAFF, clone T7-241, 1:100 
concentration, MyBioSource, #MBS241873), anti-IgA antibody (IgA, 1:16,000 concentration, Bethyl Laboratories, 
#A90-104A) or anti-IgG antibody (IgG, 1:1500 concentration, Novus Biologicals, #NB7588), using a Ventana 
Discovery XT autostainer. Serial sections of lungs or NALT were labeled with an anti-PAX5 antibody (PAX5, 
1:125 concentration, Abcam, #ab109443), using a Leica Bond RX autostainer. All slides were counterstained with 
hematoxylin. At least two H&E sections for each tissue and IHC-labeled serial sections were analyzed in a blinded 
manner by a board-certified veterinary pathologist (HT). Bright-field images were taken with an upright Eclipse 
Ni (Nikon) or constructed from digitized images using Aperio ImageScope (Leica Biosystems).
To quantify the extent of inflammation in tissue sections, H&E–stained sections of the lung tissue were dig-
itized to 20× scalable images using Aperio ScanScope (Leica Biosystems). Static 1× images were generated by 
ImageScope (Leica Biosystems). Images were classified as lung tissue, immune cell infiltrates, other tissues, blood, 
and slide glass by using Fiji. The percentage of inflammation within the lungs was determined by dividing pixels 
classified as immune cell infiltrates by pixels classified as lung tissue. Results were graphed using GraphPad Prism 
v6.0.
Gene expression analysis. RNA was isolated from frozen NALT and lungs using the RNeasy Plus Mini 
Kit (Qiagen) as per the manufacturer’s instructions. Samples were assayed using Clariom™ S mouse HT arrays 
(Affymetrix). Robust multi-array average normalization and statistical testing to determine differential expres-
sion was performed with Partek Genomics Suite 6.6. Category enrichment was tested using Enrichr56, and 
pathway analyses were performed using Ingenuity® Pathway Analysis (Qiagen). Filtering, deduplication, and 
visualizations such as scatterplots and volcano plots were performed using STATA 14.2/MP. Principal component 
analysis (PCA) was performed, and heatmaps were generated using Partek Genomics Suite 6.656,57. P values post 
adjustment for false discovery rate.
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
Statistics. Data were plotted as means ± standard errors (SEM) and analyzed using Prism 6 (GraphPad 
Software; La Jolla, CA, USA). Two-way analysis of variance (ANOVA) and student’s t-test was used for all mouse 
studies. Each figure represents one experiment. In the legend, n represents the number of animals and every 
experiment was repeated at least twice. Differences were considered significant if p < 0.05.
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